Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

Abbott Laboratories (ABT) Gross Margin: 56.38%

Is Abbott Laboratories’s gross margin high or low?

Abbott Laboratories's gross margin of 56.38% is in line with its 5-year average of 51.92%, near the high end of its 5-year range (49.96%–55.51%).

The gross margin for Abbott Laboratories (ABT) is 56.38% as of Wednesday, June 10, 2026. It is above its 12-month average by 6.04% (53.17%).

ABT Gross Margin Chart

ABT Gross Margin
55.51%+9.21% 1Y
Zoom

ABT Average Gross Margin Chart

ABT Current vs Average Gross Margin Chart

ABT Gross Margin Metrics

GROSS MARGIN

56.38%

GROSS MARGIN AVG TTM

53.17%

GROSS MARGIN AVG 3Y

51.86%

GROSS MARGIN AVG 5Y

51.92%

GROSS MARGIN AVG 10Y

51.90%

GROSS MARGIN AVG 15Y

50.87%

GROSS MARGIN AVG 20Y

52.17%

CURRENT VS TTM AVG

+6.04%

CURRENT VS 3Y AVG

+8.72%

CURRENT VS 5Y AVG

+8.58%

CURRENT VS 10Y AVG

+8.62%

CURRENT VS 15Y AVG

+10.82%

CURRENT VS 20Y AVG

+8.07%

ABT Competitors' Gross Margin

NAMEMARKET CAPGROSS MARGINTTM3Y5Y
Abbott Laboratories (ABT)$154.66B56.38%53.17%51.86%51.92%
Gilead Sciences, Inc. (GILD)$151.21B79.35%78.55%78.10%78.28%
Intuitive Surgical, Inc. (ISRG)$146.44B66.29%66.73%66.82%67.04%
Pfizer Inc. (PFE)$146.36B69.35%68.05%62.23%63.06%
Danaher Corporation (DHR)$130.25B60.68%60.22%59.98%59.48%
Thermo Fisher Scientific Inc. (TMO)$179.45B39.41%39.50%40.36%43.54%
Amgen Inc. (AMGN)$183.75B71.46%66.16%69.53%71.51%
CVS Health Corporation (CVS)$125.16B13.87%13.78%14.92%15.96%
Bristol-Myers Squibb Company (BMY)$114.14B68.75%62.23%59.55%57.82%
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B86.28%85.57%86.56%87.08%

Gross Margin Analysis

Gross Margin

56.4%

(Revenue - COGS) / Revenue

Abbott Laboratories Gross Margin Formula & Definition

Gross Margin = Gross Profit / Revenue

Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Abbott Laboratories Gross Margin FAQ

What is the gross margin for Abbott Laboratories (ABT)?
The gross margin for ABT stock is 56.38%.
Is Abbott Laboratories's gross margin high or low?
Abbott Laboratories's gross margin of 56.38% is in line with its 5-year average of 51.92%, near the high end of its 5-year range (49.96%–55.51%).
What is the TTM average gross margin for Abbott Laboratories (ABT)?
The TTM average gross margin for ABT stock is 53.17%.
What is the 3Y average gross margin for Abbott Laboratories (ABT)?
The 3Y average gross margin for ABT stock is 51.86%.
What is the 5Y average gross margin for Abbott Laboratories (ABT)?
The 5Y average gross margin for ABT stock is 51.92%.
What is the 10Y average gross margin for Abbott Laboratories (ABT)?
The 10Y average gross margin for ABT stock is 51.90%.
What is the 15Y average gross margin for Abbott Laboratories (ABT)?
The 15Y average gross margin for ABT stock is 50.87%.
What is the 20Y average gross margin for Abbott Laboratories (ABT)?
The 20Y average gross margin for ABT stock is 52.17%.

Abbott Laboratories Gross Margin History

DATEGROSS MARGIN
2025-12-3155.51%
2024-12-3150.83%
2023-12-3149.96%
2022-12-3151.14%
2021-12-3153.89%
2020-12-3150.21%
2019-12-3152.32%
2018-12-3151.75%
2017-12-3147.70%
2016-12-3153.92%
2015-12-3153.71%
2014-12-3151.81%
2013-12-3145.12%
2012-12-3127.22%
2011-12-3160.33%
2010-12-3158.56%
2009-12-3157.27%
2008-12-3157.72%
2007-12-3156.29%
2006-12-3157.14%
2005-12-3153.14%
2004-12-3154.86%
2003-12-3151.86%
2002-12-3151.90%
2001-12-3152.42%
2000-12-3154.61%
1999-12-3154.64%
1998-12-3156.77%
1997-12-3157.54%
1996-12-3157.03%

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford